Skip to content 
Search

Latest Stories

Europe acts to secure supplies of essential medicines

European Commission published its first list of critical medicines, as part of a wider overhaul of laws governing the €136 billion (£117bn) pharmaceuticals industry

Europe acts to secure supplies of essential medicines

THE European Commission published its first list of critical medicines, as part of a wider overhaul of laws governing the €136 billion (£117bn) pharmaceuticals industry aimed at avoiding shortages of drugs.

It is the biggest change to existing medical laws in two decades. The law is aimed at ensuring all Europeans have access to both innovative new treatments and generic drugs and ending huge divergences in access and prices between countries.


“The inclusion on this list is not an indication that a medicine is likely to experience a shortage in the near future. Rather, it signifies the critical importance of averting shortages for these specific medicines,” the commission said.

The list, published by the European Medicines Agency, includes a wide range of essential, generic medicines, from basic antibiotics such as amoxicillin, painkillers like paracetamol and morphine and insulin used to treat diabetes.

The list also includes some vaccines for measles, hepatitis B and tetanus.

“During 2024 the review will continue and extend to other authorised medicines in the EU not yet included in the first version,” the commission added.

Many member states are keen to see a Critical Medicines Act, similar to Critical Minerals Act, to create more resilient supply chains and avoid over-reliance on countries such as China and India that produce most generic drugs and basic equipment.

In October, the commission launched some short-term measures in order to prevent medicine shortages this winter and the next as a stop-gap while the new pharmaceutical rules are hashed out.

The new proposed law includes measures that would cut the length of basic market exclusivity that drugmakers get before generics can enter the market to eight from 10 years.

European pharmaceutical executives have repeatedly warned that this measure would backfire and accelerate a trend of waning medical innovation in the EU.

Lars Fruergaard Jorgensen, CEO of Novo Nordisk, said in November that the exclusivity reduction would not allow a pharmaceutical company to recoup the investment in development as well as the cost of marketing.

More For You

Bangladesh seeks US deal to shield garment industry from tariffs

Workers are engaged at their sewing stations in a garment factory in Savar, on the outskirts of Dhaka, on April 9, 2025. (Photo by MUNIR UZ ZAMAN/AFP via Getty Images)

Bangladesh seeks US deal to shield garment industry from tariffs

BANGLADESH, the world's second-biggest garment manufacturer, aims to strike a trade deal with the US before Donald Trump's punishing tariffs kick in next week, said the country's top commerce official.

Dhaka is proposing to buy Boeing planes and boost imports of US wheat, cotton and oil in a bid to reduce the trade deficit, which Trump used as the reason for imposing painful levies in his "Liberation Day" announcement.

Keep ReadingShow less
UK business district
The Canary Wharf business district including global financial institutions in London.
Getty Images

Bond yields ease following Starmer’s support for Reeves

THE COST of UK government borrowing fell on Thursday, partially reversing the rise seen after Chancellor Rachel Reeves became emotional during Prime Minister’s Questions.

The yield on 10-year government bonds dropped to 4.55 per cent, down from 4.61 per cent the previous day. The pound also recovered slightly to $1.3668 (around £1.00), though it did not regain all its earlier losses.

Keep ReadingShow less
modi-trump-getty
Modi shakes hands with Trump before a meeting at Hyderabad House in New Delhi on February 25, 2020. (Photo: Getty Images)
Getty Images

Indian exporters watch closely as Trump says trade deal with India likely

THE US could reach a trade deal with India that would help American companies compete more easily in the Indian market and reduce tariff rates, President Donald Trump said on Tuesday. However, he cast doubt on a similar deal with Japan.

Speaking to reporters on Air Force One, Trump said he believed India was ready to lower trade barriers, potentially paving the way for an agreement that would avoid the 26 per cent tariff rate he had announced on April 2 and paused until July 9.

Keep ReadingShow less
Kolhapuri sandal sales surge in India post Prada controversy

Customers shop for 'Kolhapuri' sandals, an Indian ethnic footwear, at a store in New Delhi, India, June 27, 2025. REUTERS/Adnan Abidi

Kolhapuri sandal sales surge in India post Prada controversy

INDIAN footwear sellers and artisans are tapping into nationalist pride stoked by the Prada 'sandal scandal' in a bid to boost sales of ethnic slippers with history dating back to the 12th century, raising hopes of reviving a struggling craft.

Sales are surging over the past week for the 'Kolhapuri' sandals that have garnered global attention after Prada sparked a controversy by showcasing similar designs in Milan, without initially crediting the footwear's origins.

Keep ReadingShow less
UK business district
The Canary Wharf business district including global financial institutions in London.
Getty Images

Economy grew 0.7 per cent in Q1 2025, fastest in a year

THE UK economy expanded at its fastest pace in a year during the first quarter of 2025, driven by a rise in home purchases ahead of a tax deadline and higher manufacturing output before the introduction of new US import tariffs.

Gross domestic product rose by 0.7 per cent in the January-to-March period, the Office for National Statistics (ONS) said, confirming its earlier estimate. This was the strongest quarterly growth since the first quarter of 2024.

Keep ReadingShow less